About this Journal Submit a Manuscript Table of Contents
Case Reports in Medicine
Volume 2012 (2012), Article ID 163173, 4 pages
http://dx.doi.org/10.1155/2012/163173
Case Report

Fenofibrate Therapy in Carnitine Palmitoyl Transferase Type 2 Deficiency

1Griffith University School of Medicine and Gold Coast University Hospital, Southport, Gold Coast, QLD 4215, Australia
2Royal Australasian College of Physicians and Royal Melbourne Hospital, Parkville, Melbourne, VIC 3050, Australia
3Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD 4029, Australia
4Department of Cardiology, Gold Coast University Hospital, Griffith University, Southport, Gold Coast, QLD 4215, Australia

Received 11 September 2012; Accepted 16 November 2012

Academic Editor: Christoph Wanner

Copyright © 2012 I. Hamilton-Craig et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Sigauke, D. Rakheja, K. Kitson, and M. J. Bennett, “Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review,” Laboratory Investigation, vol. 83, no. 11, pp. 1543–1554, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. P. Bonnefont, J. Bastin, A. Behin, and F. Djouadi, “Bezafibrate for an inborn mitochondrial beta-oxidation defect,” New England Journal of Medicine, vol. 360, no. 8, pp. 838–840, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. “Australian absolute cardiovascular disease risk calculator,” http://www.cvdcheck.org.au/.
  4. M. J. Budoff, S. Achenbach, R. S. Blumenthal et al., “Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging, council on clinical cardiology,” Circulation, vol. 114, no. 16, pp. 1761–1791, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Hoff, E. V. Chomka, A. J. Krainik, M. Daviglus, S. Rich, and G. T. Kondos, “Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35,246 adults,” American Journal of Cardiology, vol. 87, no. 12, pp. 1335–1339, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Vreken, A. E. M. van Lint, A. H. Bootsma, H. Overmars, R. J. A. Wanders, and A. H. van Gennip, “Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidaemias and fatty acid oxidation defects,” Journal of Inherited Metabolic Disease, vol. 22, no. 3, pp. 302–306, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. G. D. Vladutiu, “The molecular diagnosis of metabolic myopathies,” Neurologic Clinics, vol. 18, no. 1, pp. 53–104, 2000. View at Scopus
  8. I. Hamilton-Craig, “Update on lipid management: commonly asked questions,” Medicine Today, vol. 13, no. 1, pp. 33–42, 2012.
  9. I. Hamilton-Craig, “Managing myopathy in the statin-intolerant patient,” Cardiology Today, vol. 2, no. 4, pp. 15–19, 2012.
  10. S. Yamaguchi, H. Li, J. Purevsuren et al., “Benzafibrate can be a new treatment option for mitochondrial fatty acid oxidation orders: evaluation by in vitro probe acylcarnitine assay,” Molecular and Genetic Metabolism, vol. 107, no. 1-2, pp. 87–91, 2012. View at Publisher · View at Google Scholar
  11. J. P. Bonnefont, J. Bastin, P. Laforêt et al., “Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency,” Clinical Pharmacology and Therapeutics, vol. 88, no. 1, pp. 101–108, 2010. View at Publisher · View at Google Scholar · View at Scopus